Neuralgia Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

Online Pharmacies is the fastest growing sector, North America is the largest market

The Global Neuralgia Treatment Market is projected to expand significantly, growing from USD 1.34 billion in 2025 to USD 2.23 billion by 2031, at a Compound Annual Growth Rate (CAGR) of 8.86%. This market includes various pharmacological and interventional therapies aimed at managing neuropathic pain, a chronic condition characterized by nerve damage resulting in sharp, shooting, or burning sensations. The primary forces propelling this market's growth are the rapidly increasing global elderly population, who are particularly vulnerable to conditions like postherpetic neuralgia, and the rising incidence of chronic metabolic disorders such as diabetes, which frequently lead to peripheral neuropathy.

Despite this growth, market expansion faces significant hurdles, notably adverse drug effects and complex diagnostic procedures, which often lead to patient non-compliance or untreated cases. A major barrier to effective care delivery and market penetration is the high rate of underdiagnosis. For instance, the American Diabetes Association indicated that in 2025, distal symmetric polyneuropathy might affect at least 10% to 15% of newly diagnosed type 2 diabetes patients. This highlights the substantial number of patients needing early neuropathic management who remain undiagnosed, thereby limiting the accessible market for existing treatments.

Market Drivers

The increasing prevalence of diabetes and its associated diabetic neuropathy serves as a fundamental catalyst for the Global Neuralgia Treatment Market. Chronic high blood sugar levels systematically damage peripheral nerves, creating a large patient pool suffering from painful diabetic neuropathy (PDN) who require ongoing analgesic or anticonvulsant therapy. This expanding demographic demands a continuous rise in the development and prescription of solutions for neuropathic pain management. According to the International Diabetes Federation's December 2025 'IDF Diabetes Atlas 11th Edition', approximately 589 million adults globally were living with diabetes in 2024, ensuring that diabetic neuropathy remains a dominant clinical indication driving market demand, as a significant portion will eventually require intervention for nerve damage.

Simultaneously, continuous advancements in both pharmacological and surgical pain management interventions are aggressively broadening the market's scope. Manufacturers are increasingly prioritizing the creation of non-opioid pharmaceuticals and sophisticated neuromodulation devices to overcome the limitations of traditional treatments. This strategic shift is marked by substantial investments and key regulatory milestones that enhance both treatment efficacy and patient safety, as evidenced by Boston Scientific's October 2025 acquisition of Nalu Medical for about $533 million to integrate advanced peripheral nerve stimulation technologies. Furthermore, regulatory approvals for next-generation systems, like the U.S. FDA's 2025 approval for Saluda Medical's EVA programming platform to optimize spinal cord stimulation outcomes, are accelerating their adoption.

Market Challenges

Diagnostic complexities present a significant obstacle to the expansion of the global neuralgia treatment market. Neuropathic pain is often subjective and challenging to identify using standard clinical tests, especially in its early stages. Because these sensations can resemble those of other medical conditions, healthcare providers frequently struggle to accurately pinpoint the specific nerve damage, often resulting in delayed or missed diagnoses. When patients do not receive a definitive diagnosis, they cannot be prescribed the necessary pharmacological or interventional therapies, effectively preventing their entry into the consumer base for these treatments.

This high rate of underdiagnosis directly limits the total addressable market size. Without a confirmed diagnosis, patients do not generate demand for prescription analgesics or neurostimulation devices, creating a substantial gap between the actual disease prevalence and treatment revenue. The Foundation for Peripheral Neuropathy estimated that in 2025, around 30 million people in the United States suffered from some form of peripheral neuropathy, yet a considerable number remained untreated due to these diagnostic challenges. This disparity underscores a substantial amount of potential market value that remains inaccessible due to current clinical limitations.

Market Trends

The development of selective voltage-gated sodium channel blockers signifies a transformative change in pharmacological interventions, shifting from broad-spectrum analgesics to precisely targeting peripheral pain signals. This trend focuses on inhibiting specific ion channels, such as NaV1.8, which are highly expressed in nociceptors and crucial for transmitting neuropathic pain, crucially avoiding the central nervous system side effects associated with opioids. The validation of this mechanism has rapidly accelerated, establishing a new class of therapeutics that directly addresses the physiological origin of neuralgia, exemplified by Vertex Pharmaceuticals' January 2025 announcement of U.S. FDA approval for suzetrigine, a highly selective NaV1.8 pain signal inhibitor, marking the first new medicine class for acute pain in over two decades and advancing its Phase 3 development in diabetic peripheral neuropathy.

Concurrently, advancements in next-generation neuromodulation devices are redefining the interventional landscape through the deployment of closed-loop systems that adapt to patient physiology in real-time. Unlike traditional fixed-output stimulators, these innovative devices use sophisticated sensing technology to detect Evoked Compound Action Potentials (ECAPs), enabling the system to automatically adjust stimulation levels based on the patient's spinal cord activity and body movements. This capability ensures optimal therapeutic efficacy while preventing overstimulation often triggered by daily activities like coughing or bending, a pivotal expansion demonstrated by Medtronic's March 2025 announcement of the availability of its Inceptiv closed-loop rechargeable spinal cord stimulator, which senses biological signals 50 times per second to deliver consistent therapy for chronic pain patients.

Key Market Players

• GSK PLC
• Pfizer Inc
• Novartis AG
• Biogen Inc
• Cadila Pharmaceuticals Ltd
• Lundbeck Pharmaceuticals Ltd
• Zydus Group
• Eli Lily and Company
• Allergan Inc.
• Baxter International Inc.

Report Scope

In this report, the Global Neuralgia Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Neuralgia Treatment Market, by Treatment:

• Drug-Based
• Surgery

Neuralgia Treatment Market, by Indication:

• Diabetic Neuropathy
• Intercostal Neuralgia
• Occipital Neuralgia
• Peripheral Neuralgia
• Postherpetic Neuralgia
• Trigeminal Neuralgia

Neuralgia Treatment Market, by Distribution Channel:

• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies

Neuralgia Treatment Market, by Region:

• North America
• Europe
• Asia Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Neuralgia Treatment Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.